Beijing, China — Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", stock code: 603087.SH) in partnership with Getz Pharma from Pakistan, recently hosted a conference on diabetes treatment in Beijing. The event aimed to strengthen medical and health collaboration between China and Pakistan, along with other nations involved in the Belt and Road Initiative, focusing on innovative approaches to managing diabetes.

The event, held at Gan & Lee's headquarters in Beijing, drew an impressive turnout of 226 doctors and medical experts from ten countries, including Pakistan, Kenya, Nigeria, Myanmar, Cambodia, Philippines, Uzbekistan, Sri Lanka, Uganda, and South Sudan. The gathering served as a platform for these professionals to share insights and discuss advancements in diabetes care.

The conference was led by Mr. Du Kai, CEO of Gan & Lee, and Dr. Jahanzeb K. Khan, spokesperson for Getz Pharma International Medical Affairs, highlighting the significance of this collaborative effort in deepening medical ties between China and Pakistan within the Belt and Road framework. This international academic exchange marks a significant step forward in addressing the global challenge of diabetes through shared knowledge and cooperation.

During the conference, Gan & Lee CEO, Mr. Du Kai, highlighted the strong collaboration between China and Pakistan in promoting the high-quality development of the Belt and Road initiative. Mr. Du Kai shared insights into the joint efforts by both countries to tackle a major global health challenge—diabetes. In his presentation on insulin products, Mr. Du Kai detailed Gan & Lee's accomplishments and effortsin maintaining product quality, ensuring safety, and promoting the global accessibility of insulin.

Furthermore, Gan & Lee extended an invitation to the attendees for a guided tour of production facilities and Research & Development (R&D) center. These tours provided the delegates with an up-close look at the insulin manufacturing process and offered insights into Gan & Lee's stringent quality control measures and cutting-edge R&D platform, which is leading the way in diabetes treatment solutions. The visiting experts highly praised Gan & Lee's R&D capabilities and meticulous approach to diabetes care.

In South Asia, Pakistan plays a crucial role as a partner for China in the Belt and Road initiative. Both countries are among the top three globally in terms of the number of diabetic patients, with China leading and Pakistan ranking third, according to the International Diabetes Federation (IDF). This places them in a similar position to address healthcare challenges, particularly in diabetes treatment. Recent 2021 data reveals that the prevalence of diabetes is 13% in China and a staggering 26.7% in Pakistan¹. However, treatment rates in both countries, at 66.8%² and 54.3%³ respectively, fall below the global average of 71.6%⁴, indicating a critical need for improved diabetes management and care.

Eligible diabetes patients often delay starting insulin therapy for various reasons, as highlighted in research by Sharma SK et al. These reasons include concerns about clinical effectiveness, fear of hypoglycemia, lack of guidance on using injection pens, and the high cost of insulin. Notably, 38% of patients postpone starting insulin therapy due to its high price, and 63% of those in low-income countries find it unaffordable⁵. Such delays can significantly increase the risk of severe diabetic complications⁶. In response to these challenges, Gan & Lee is dedicated to enhancing diabetes treatment options. The company is actively expanding into international markets to improve the accessibility and affordability of its third-generation insulin products.

In line with the principles of the Belt and Road initiative, Gan & Lee is dedicated to strengthening global partnerships to provide top-notch medicines and services worldwide. The recent academic exchange conference not only bolstered collaborative efforts between China and Pakistan in diabetes management but also served as a platform for medical experts from various countries to come together, exchange ideas, and form partnerships. This event promoted international cooperation and contributed to advancements in diabetes care. Looking ahead, Gan & Lee is committed to expanding its collaborations with medical and pharmaceutical experts worldwide, with a focus on enhancing the availability of high-quality diabetes treatment options for patients globally.

References：

1. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/

2. Khunti K, et al. Diabetes Obes Metab. 2016;18(4):401-409. doi:10.1111/dom.12626.

3. Rattelman CR, et al. Diabetes Ther 2021;12:581-594. doi: 10.1007/s13300-020-00993-w.

4. Li Y, Teng et al. BMJ 2020 Apr 28;369:m997. doi: 10.1136/bmj.m997.

5. Sharma SK, et al. Eur Endocrinol 2020;16:143-147. doi: 10.17925/EE.2020.16.2.143.

6. Khunti K, Millar-Jones D. Prim Care Diabetes 2017;11:3-12. doi: 10.1016/j.pcd.2016.09.003.

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.